Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

ABSTRACT: Ref: Protocol v7.0, dated 23Mar2022. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.

DISEASE(S): Metastatic Colorectal Cancer,Irresecable O Metastásico Localmente Avanzado, Inestabilidad De Microsatélites Alta (msi-h) O Dmmr Crc Que Son Elegibles Para La Primera Línea De Tratamiento Anti-pd-1,Solid Tumor, Adult,Locally Advanced Unresectable Or Metastatic, Microsatellite Instability High (msi-h) Or Dmmr Crc Who Are Eligible For Anti-pd-1 1st Line Of Treatment,Neoplasms

PROVIDER: 2312569 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional expression data from vaccinia/HIV-1 vaccine immunized healthy subjects [in vivo]

Project description:In a phase 2 trial, participants received 3 DNA/HIV-1 primes and a recombinant TV (rTV)/HIV-1 boost at 8 weeks (8-wk group) or 24 weeks (24-wk group) post-final prime. We investigated the vaccinia-specific immunological and overall transcriptomic responses to the rTV/HIV-1 boost.

2020-12-31 | GSE118976 | GEO

NK cell immune responses differ after prime and boost vaccination

Project description:A better understanding of innate responses induced by vaccination is critical for designing optimal vaccines. Here, we studied the diversity and dynamics of the NK cell compartment after prime-boost immunization with the modified vaccinia virus Ankara using cynomolgus macaques as a model. Mass cytometry was used to deeply characterize blood NK cells. The NK cell subphenotype composition was modified by the prime. Certain phenotypic changes induced by the prime were maintained over time and, as a result, the NK cell composition prior to boost differed from that before prime. The key phenotypic signature that distinguished NK cells responding to the boost from those responding to the prime included stronger expression of several cytotoxic, homing, and adhesion molecules, suggesting that NK cells at recall were functionally distinct. Our data reveal potential priming or imprinting of NK cells after the first vaccine injection. This study provides novel insights into prime-boost vaccination protocols that could be used to optimize future vaccines.

2019-02-19 | E-MTAB-7697 | biostudies-arrayexpress

The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost

Project description:Different COVID-19 vaccine modalities expressing the same SARS-CoV-2 spike antigen present a unique opportunity to contrast the immunologic outcomes associated with each vaccine platform. Here we characterized the memory B cell response elicited by 12 different combinations of primary series and boost vaccines spanning adenovirus vector, mRNA and subunit protein technologies. Cross-reactive B cells for ancestral virus and Omicron BA.1 expanded in similar proportions across all vaccine regimens. However, mRNA boost following adenovirus vector prime resulted in the greatest increase in antigen-specific B cell frequencies, predominantly of a highly activated ‘atypical’ B cell subset, identified by flow cytometry and single-cell sequencing. Using lineage tracking by single-cell IG sequencing we characterized B cell lineages exhibiting different phenotypes at subsequent time-points. Furthermore, the same mRNA boost induced markedly different memory B cell phenotypes depending on the modality of the prime, suggesting that the type of response elicited by boosting is dependent on the nature of pre-existing memory B cells imprinted by the vaccine priming.

2026-01-31 | GSE282932 | GEO

Whole blood RNAseq of SIVmac239-infected Mamu-B*08+/- indian rhesus macaques with and without heterologous adenovirus-vector SIV vaccination

Project description:Investigation of the transcriptional response in whole blood following SIVmac239 infection in Macaca mulatta vaccinated with heterologous prime-boost adenovirus-vector SIVmac239 Vif and Nef.

2024-10-07 | GSE272837 | GEO

Interaction of adjuvants, sex, and the microbiome on SIV vaccine-induced immunity and protective efficacy in rhesus macaques

Project description:Mucosal priming of rhesus macaques with replicating Adenovirus SIV-recombinants and systemic boosting with ALVAC-SIV plus envelope protein or DNA encoding SIV genes plus envelope protein elicited strong immunologic responses in both compartments. Following repeated low-dose intrarectal SIV challenges, significant acquisition delay compared to adjuvant controls was not observed. However, delayed acquisition in both vaccine arms and adjuvant controls compared to naïve controls led to identification of transcriptomic signatures associated with protective innate immunity. Vaccinated females but not males exhibited significantly lower acute viremia compared to same-sex controls, confirming our previously reported sex-difference in SIV vaccine outcomes. The rectal microbiome of females and males responded differently to the prime-boost regimen and differentially associated with viremia control and systemic and mucosal humoral immunity. We conclude that the impact on protective efficacy of vaccine-induced microbiome alteration in males and females and trained immunity are factors of significant importance in vaccine outcome.

2025-11-20 | GSE141341 | GEO

RNA-Seq of mouse lung vaccinated with subcutaneous BCG and two novel tuberculosis mucosal boosting nanovaccines

Project description:Mice were left unvaccinated (Naive) or vaccinated with either BCG alone (BCG) or BCG followed by two intranasal boosting of novel nanovaccines Nano-FP1 or Nano-FP2, 12 and 14 weeks later. A group of mice were also administered a 3rd boost of the corresponding nanovaccine 25 weeks after sc. BCG. Mice were sacrificed at 2, 11 and 14 weeks after second boosting, and bronchoalveolar lavage (BAL) and lung parenchyma (Lung) were extracted for RNA-Seq. The group of mice administered a 3rd boosting was the group sacrificed at 14 weeks time-point.

2021-01-28 | E-MTAB-9449 | biostudies-arrayexpress

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Project description:This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.

| 2061109 | ecrin-mdr-crc

T-cell immunogenicity, gene expression profile and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers – results of the randomized multi-arm phase I/II ANRS VRI01 trial

Project description:Heterologous prime-boost strategies are of interest for HIV vaccine development. The order of prime-boost components could be important for the induction of T-cell responses. In this phase I/II multi-arm trial, three vaccine candidates were used as prime or boost: MVA HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (5 lipopeptides from Gag, Pol, Nef); DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, Env gp160 clade B). Healthy volunteers (n=92) were randomized to four groups: 1) MVA at weeks (W) 0/8 + LIPO-5 at W20/28 (M/L); 2) LIPO-5 at W0/8 + MVA at W20/28 (L/M); 3) DNA at W0/4/12 + LIPO-5 at W20/28 (G/L); 4) DNA at W0/4/12 + MVA at W20/28 (G/M). Frequency of IFNγ-ELISpot responders at W30 was 33%, 43%, 0% and 74%, respectively. Only MVA-receiving groups were further analyzed. Gene expression profiles of 79 subjects at different timepoints were analyzed by Illumina Whole-Genome Gene Expression BeadChips. Significant whole blood gene expression changes were observed two weeks after the first MVA injection, regardless of its use as prime or boost. An MVA gene signature was identified, including 86 genes mainly related to cell cycle pathways. Three prime-boost strategies led to CD4+ and CD8+ T cell responses and to a whole blood gene expression signature primarily due to their MVA HIV-B component.

2022-04-15 | GSE196172 | GEO

mRNA-LNP HIV-1 trimer boosters elicit precursors to bnAbs

Project description:Germline-targeting (GT) HIV vaccine strategies are predicated on deriving broadly neutralizing antibodies (bnAbs) through multiple boost immunogens. However, as the recruitment of memory B cells (MBCs) to germinal centers (GCs) is inefficient and may be derailed by serum antibody-induced epitope masking, driving further B cell receptor (BCR) modification in GC-experienced B cells after boosting poses a challenge. Using humanized Ig knockin mice, we found that GT protein trimer immunogen N332-GT5 could prime inferred-germline precursors to the V3-glycan-targeted bnAb BG18, and that B cells primed by N332-GT5 were effectively boosted by either of two novel protein immunogens designed to have minimum cross-reactivity with the off target V1-binding responses. The delivery of the prime and boost immunogens as mRNA-LNPs generated long-lasting GCs, somatic hypermutation, and affinity maturation, and may, therefore, be an effective tool in HIV vaccine development.

2024-02-26 | MSV000094176 | MassIVE

T cell-inducing heterologous vaccine against elephant endotheliotropic herpesvirus

Project description:We developed a heterologous, recombinant modified vaccinia virus Ankara prime and adjuvanted protein boost vaccine, containing the regulatory protein EE2 and the major capsid protein. The vaccine design focussed on targeting Th1 and cytotoxic T cell responses, which are crucial to herpesvirus immunity. In a proof-of-concept trial, safety and immunogenicity were tested in adult elephants. We used a modified interferon-γ release (IFNG) point-of-care vaccine-specific whole blood assay to determine T cell responses by RT-qPCR first, established to overcome quality-reducing sample transport times to the laboratory. Subsequently, RNA sequencing was utilised to understand transcriptomic changes induced by the vaccine.

2025-07-24 | GSE297105 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data